Keynote 024 5 Year Course. — roy herbst, md, phd. Bar lengths indicate duration of treatment (first‐course, dark green;
Pembrolizumab (keytruda) has received fda approval for the frontline treatment of patients with metastatic non small cell lung cancer. — roy herbst, md, phd.